These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11825329)

  • 21. Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease.
    Verhoeff NP
    Expert Rev Neurother; 2005 Mar; 5(2):277-84. PubMed ID: 15853497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease: clinical treatment options.
    Reichman WE
    Am J Manag Care; 2000 Dec; 6(22 Suppl):S1125-32; discussion S1133-8. PubMed ID: 11142177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease].
    Franke AG; Lieb K; Fellgiebel A
    Fortschr Neurol Psychiatr; 2009 Jun; 77(6):326-33. PubMed ID: 19504422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy.
    Zhang H; Peng Y; Zhuo L; Wang Y; Zeng G; Wang S; Long L; Li X; Wang Z
    Eur J Med Chem; 2022 Nov; 242():114695. PubMed ID: 36044812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological treatment of dementia.
    Schwarz S; Froelich L; Burns A
    Curr Opin Psychiatry; 2012 Nov; 25(6):542-50. PubMed ID: 22992546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG
    Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.
    Wynn ZJ; Cummings JL
    Dement Geriatr Cogn Disord; 2004; 17(1-2):100-8. PubMed ID: 14564129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current issues in dementia pharmacotherapy.
    Daiello LA
    Am J Manag Care; 2007 Dec; 13 Suppl 8():S198-202. PubMed ID: 18095783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The neurobiology and pharmacotherapy of Alzheimer's disease.
    Felician O; Sandson TA
    J Neuropsychiatry Clin Neurosci; 1999; 11(1):19-31. PubMed ID: 9990552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison table: drugs for Alzheimer's disease.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):e160-e161. PubMed ID: 28922344
    [No Abstract]   [Full Text] [Related]  

  • 32. A review: treatment of Alzheimer's disease discovered in repurposed agents.
    Appleby BS; Nacopoulos D; Milano N; Zhong K; Cummings JL
    Dement Geriatr Cogn Disord; 2013; 35(1-2):1-22. PubMed ID: 23307039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients.
    Sirviö J
    Gerontology; 1999; 45 Suppl 1():3-14. PubMed ID: 9876213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy.
    Zheng H; Fridkin M; Youdim MB
    Curr Drug Targets; 2012 Jul; 13(8):1089-106. PubMed ID: 22676912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
    Blaszczyk AT; Mang BH; Garza H; Mathys M
    Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors.
    Hogan DB; Patterson C
    Can J Neurol Sci; 2002 Nov; 29(4):306-14. PubMed ID: 12463485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholinesterase inhibition: is there evidence for disease-modifying effects?
    Shanks M; Kivipelto M; Bullock R; Lane R
    Curr Med Res Opin; 2009 Oct; 25(10):2439-46. PubMed ID: 19678754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds.
    Colombres M; Sagal JP; Inestrosa NC
    Curr Pharm Des; 2004; 10(25):3121-30. PubMed ID: 15544502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapy of Alzheimer's disease: current status and future development].
    Schmidt R; Neff F; Lampl C; Benke T; Anditsch M; Bancher C; Dal-Bianco P; Reisecker F; Marksteiner J; Rainer M; Kapeller P; Dodel R
    Neuropsychiatr; 2008; 22(3):153-71. PubMed ID: 18826870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.